Emcure Pharma IPO description – Emcure is a leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. It is ranked as (i) the 12th largest pharmaceutical company in India and (ii) the largest pharmaceutical company in India in the gynecology, blood related and HIV antivirals therapeutic areas, based on sales in India in the FY2021. It is an R&D driven company with a differentiated product portfolio that includes orals, injectables and biologics, as well as an mRNA platform through which it is currently developing a COVID-19 vaccine.
Emcure’s products are sold across over 70 countries with a strong presence in Europe and Canada. The company has experienced rapid growth in recent years and it is one of the fastest growing pharmaceutical companies in India. Between the FY2019 and the FY2021, its total sales in India grew at a CAGR of 11.28% from INR32,856 million to INR40,686 million, outperforming the Indian pharmaceutical industry’s overall growth in sales in India, which grew at a CAGR of 5.78%.
The company is present in most of the major therapeutic areas, including, gynecology, cardiovascular, vitamins, minerals and nutrients, oncology/anti-neoplastic, HIV and blood-related. Across all such therapeutic areas, it is ranked among the top 10 pharmaceutical companies in India in terms of sales in India in the FY2021.
Promoters of Emcure Pharma – Satish Mehta and Sunil Mehta
Emcure Pharma IPO Details
| Subscription Dates | Coming soon |
| Price Band | INR – per share |
| Fresh issue | INR1,100 crore |
| Offer For Sale | 18,168,356 shares |
| Total IPO size | Coming soon |
| Minimum bid (lot size) | Coming soon |
| Face Value | INR 10 per share |
| Retail Allocation | 35% |
| Listing On | NSE, BSE |
Emcure Pharma’s Financial Performance
| FY2019 | FY2020 | FY2021 | |
| Revenue | 4,815.6 | 5,130.9 | 6,091.8 |
| Expenses | 4,469.5 | 4,922.1 | 5,345.9 |
| Net income | 236.8 | 134.5 | 418.6 |
| Margin (%) | 4.9 | 2.6 | 6.9 |
Emcure Pharma IPO News
- Emcure IPO RHP
- Emcure IPO DRHP
Emcure Pharma Valuations & Margins
| FY2019 | FY2020 | FY2021 | |
| EPS | 10.47 | 4.62 | 21.68 |
| PE ratio | – | – | NA |
| RONW (%) | 10.35 | 4.37 | 17.25 |
| ROCE (%) | 14.85 | 11.67 | 22.64 |
| EBITDA (%) | 18.32 | 15.32 | 20.80 |
| Debt/Equity | – | – | – |
| NAV | 101.15 | 105.72 | 125.68 |
Emcure Pharma IPO GMP Daily Trend
| Date | Emcure Pharma IPO GMP | Kostak | Subject to Sauda |
Emcure Pharma IPO Subscription – Live Updates
| Category | Shares Offered | Day 1 | Day 2 | Day 3 |
| QIB | ||||
| NII | ||||
| Retail | ||||
| Employees | ||||
| Total |
Emcure Pharma IPO Reviews – Subscribe or Avoid?
Angel One –
Arihant Capital –
Ashika Research –
Asit C Mehta –
BP Wealth –
Canara Bank Securities –
Choice Broking –
Elite Wealth –
GEPL Capital –
Hem Securities –
ICICIdirect –
KR Choksey –
Marwadi Financial Services –
Motilal Oswal –
Nirmal Bang –
Religare Broking –
Samco Securities –
SMC Global –
Ventura Securities –
Emcure Pharma Offer Registrar
Link Intime India Private Limited
C-101, 1st Floor,
247 Park, Lal Bahadur Shastri Marg,
Vikhroli (West), Mumbai 400 083,
Maharashtra, India
Phone: +91 22 4918 6200
Fax: +91 22 4918 6195
Email: [email protected]
Website: www.linkintime.co.in
Emcure Pharma Contact Details
Emcure Pharmaceuticals Limited
14th Floor, Tower 3, Plot No. P2, IT-BT Park
Phase II, M.I.D.C., Hinjawadi,
Pune – 411057,
Maharashtra, India
Phone: +91 22 7181 8181
Email: [email protected]
Website: www.emcure.com
Emcure Pharma IPO Allotment Status
Emcure Pharma IPO allotment will be available on Link Intime’s website. Click on this link to get allotment status.
Emcure Pharma IPO Timetable
| IPO Opening Date | Coming soon |
| IPO Closing Date | Coming soon |
| Finalisation of Basis of Allotment | Coming soon |
| Initiation of refunds | Coming soon |
| Transfer of shares to demat accounts | Coming soon |
| Listing Date | Coming soon |
| Opening Price on NSE | Coming soon |
| Closing Price on NSE | Coming soon |
Emcure IPO FAQs
How many shares in Emcure Pharma IPO are reserved for HNIs and retail investors?
The investors’ portion for QIB – 50%, NII – 15%, and Retail – 35%.
How to apply in Emcure Public Offer?
The best way to apply in Emcure IPO is through Internet banking ASBA (know all about ASBA here). You can also apply online through your stock broker using UPI. If you prefer to make paper applications, fill up an offline IPO form and deposit the same to your broker.
What is Emcure Pharma IPO GMP today?
Emcure Pharma IPO GMP today is NA per share.
What is Emcure IPO kostak rate today?
Emcure IPO kostak rate today is NA per application.
What is Emcure Pharma Subject to Sauda rate today?
Emcure Pharma Subject to Sauda rate today is NA per application.